Journal List > Korean J Lab Med > v.30(2) > 1011628

Seong, Yeo, Cho, Park, Kim, Paek, Kim, Jung, Park, Kim, Kim, and Park: Molecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report of Four Novel Mutations

Abstract

Background:

Neurofibromatosis type 2 (NF2) is an autosomal dominant syndrome caused by the NF2 tumor suppressor gene. However, the NF2 mutation characteristics in Korean patients are not sufficiently understood. In this study, we conducted a comprehensive mutational analysis in 7 Korean NF2 patients by performing direct sequencing and gene-dosage assessment.

Methods:

We analyzed all exons and flanking regions of NF2 by direct sequencing and screened the deletions or duplications involving NF2 by multiplex ligation-dependent probe amplification.

Results:

Four novel NF2 mutations, including 2 splice-site mutations (c.364-1G>A and c.886-3C>G), 1 frameshift mutation (c.524delA), and 1 missense mutation (c.397T>C; p.Cys133Arg), were identified in our patients. No large deletion or duplication was identified in our series. Subsequently, we identified an abnormal splicing product by using reverse transcription-PCR and direct sequencing in 2 patients with a novel splice-site mutation. The missense mutation c.397T>C was predicted to have harmful effects on protein function.

Conclusions:

The detection rate of NF2 mutations in Korean patients (57%) is similar to those in other populations. Our results provided a greater insight into the mutational spectrum of the NF2 gene in Korean subjects.

REFERENCES

1.Evans DG., Huson SM., Donnai D., Neary W., Blair V., Newton V, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992. 84:603–18.
2.Wallace AJ., Watson CJ., Oward E., Evans DG., Elles RG. Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis. Genet Test. 2004. 8:368–80.
3.Kluwe L., Nygren AO., Errami A., Heinrich B., Matthies C., Tatagiba M, et al. Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer. 2005. 42:384–91.
4.Yang HJ., Won YJ., Park KJ., Jung HW., Choi KS., Park JG. Germline mutations of the NF2 gene in Korean neurofibromatosis 2 patient. J Korean Cancer Assoc. 1998. 30:790–9.
5.Ferrer-Costa C., Orozco M., de la Cruz X. Sequence-based prediction of pathological mutations. Proteins. 2004. 57:811–9.
crossref
6.Ng PC., Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001. 11:863–74.
crossref
7.Ramensky V., Bork P., Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002. 30:3894–900.
crossref
8.Ahronowitz I., Xin W., Kiely R., Sims K., MacCollin M., Nunes FP. Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat. 2007. 28:1–12.
9.Evans DG., Trueman L., Wallace A., Collins S., Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998. 35:450–5.
crossref
10.Baser ME., Kuramoto L., Joe H., Friedman JM., Wallace AJ., Gillespie JE, et al. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet. 2004. 75:231–9.
crossref

Fig. 1.
Results of RT-PCR and sequence analysis for the 2 splice-site mutations c.364-1G>A (patient P4) and c.886-3C>G (patient P2). (A) The c.364-1G>A mutation yields a 0.55-kb abnormal product as well as 0.63-kb normal product in RT-PCR with the following primers: F-5′-AAGCAACCCAAGACGTTCAC-3′, R-5′-CCGGATTGCAAAGTAGTTCA-3′. (B) The c.886-3C>G cannot be discriminated from normal products by using following primers: F-5′-CTGACCCCCAAGATCTCCT-3′, R-5′-GCTTCAGCTGATCTGCCTCT-3′. (C) Exon 4 skipping is shown in the cDNA sequence of patient 4 with c.364-1G>A. (D) Patient P2 is heterozygous for c.886-3C>G, and 2-bp insertion of AG (blue) between exon 9 (yellow) and exon 10 (pink) is shown in the cDNA sequence. This insertion is caused by the introduction of a new splice acceptor site from c.886-4A to c.886-3C>G and subsequent inclusion of original splice acceptor site (c.886-2_-1AG) in the mature transcript.
kjlm-30-190f1.tif
Fig. 2.
Multiple alignment and amino acid conservation for a novel missense mutation c.397T>C (p.Cys133Arg). The cysteine at codon 133 is well-conserved among various species.
kjlm-30-190f2.tif
Table 1.
Manchester clinical diagnostic criteria for neurofibromatosis type 2
A) Bilateral vestibular schwannomas
B) First-degree family relative with NF2 AND
- Unilateral vestibular schwannoma OR
- Any 2 of the following: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular lenticular opacities
C) Unilateral vestibular schwannoma AND any 2 of the following: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular lenticular opacities
D) Multiple meningiomas (2 or more) AND
- Unilateral vestibular schwannoma OR
- Any 2 of the following: schwannoma, glioma, neurofibroma, cataract
Table 2.
Primer sequences used in this study
Exon Name Sequence (5′→3′) PCR product size (bp)
1 1-1F GGGAAAGTCCTGCCTACCTT 542
  1-1R CCTGCACTCTGAGCCCTTTA  
  1-2F ACTCCCCTTTCCGCTCAG 540
  1-2R CAGGAGCATCCAGCTTCTTC  
2 2F TTTCCCACTCATGGGTTTGT 579
  2R AGGCATAAAGCCAGAAGCAA  
3 3F CTGTGGCCCTGAGAACATTT 670
  3R GGACCCATTTTCAAGGAGGT  
4 4F CTCTCCACCTGTCTGCATCA 481
  4R TCTGCACACCACACACACAC  
5 5F AAACATGCCCACATTTCCAT 545
  5R CTAGTCCTGGTGACCCCAAA  
6 6F GATGGCTTCTGAGCATGTGA 564
  6R CCAGCTCTCCCCTTTTCTTT  
  6-1R GCCCATAAAGGAATGTAAACCA  
  6-2R CTTTAAGGCAAAAAAAAAAAAAAAAG  
7 7F GGATGGGAAATTCTGCTTGA 588
  7R GGACGGAGATCTCACAGAGC  
8 8F CTTCTACCTGCCCCAATTCA 452
  8R AACAACCACACCCTCAAAGC  
9 9F TCAAGAATCCCTTCCCACAC 446
  9R GCGCCAAGTGAGATACCATT  
10 10F TGCATGTTTCCAGAGCTGAC 591
  10R GATGCATGCACTCTTGGCTA  
11 11F TGTTTTTCAAGTGGCACAGC 582
  11R GTAGTGCCCAGGCTGAGAAG  
12 12F GGGAATGTGGCTTGTCATTT 585
  12R ACTGAGTTCCTGTGCCCAAC  
13 13F GCTGCAGAAGGTCTGGTTTC 513
  13R GCTCTCTGCACCTCTCATCC  
14 14F ATGTGGAGGGAGTGAAGTGG 440
  14R CCAGGGTGTAAGAGCAGAGC  
15 15F ACCCTAGATCGCACACCAAG 523
  15R GGCTCAAAATCCACCCTGTA  
16 16F TCACGATTTCAGGCCTATCC 492
  16R ATGCCACCAAGACAAAGGAC  
17 17F TGTCAAGAGGCAATGCTGAC 462
  17R CTCAGCTGGGGAAAGTTCTG  
Table 3.
Clinical features and molecular findings of the 7 patients who participated in this study
No. Sex Age at onset (yr) Vestibular schwannoma Other tumor Family history Mutation Effect on amino acid
P1 Female 4 Bilateral Multiple schwannomas Simplex c.524delA p.Asn175IlefsX5
P2 Male 19 Bilateral Multiple meningiomas, schwannoma Familial c.886-3C>G Frameshift due to abnormal splicing
P3 Male 41 Unilateral - Familial c.397T>C p.Cys133Arg
P4 Female 27 Bilateral Multiple meningiomas Simplex c.364-1G>A Exon 4 skipping due to abnormal splicing
P5 Male 60 Unilateral Multiple schwannomas Simplex - -
P6 Female 65 Unilateral Meningioma, schwannoma Simplex - -
P7 Male 30 Bilateral Multiple meningiomas Simplex - -
TOOLS
Similar articles